View in EDS HTML Full Text PDF Full Text

Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer.

Saved in:
Bibliographic Details
Title: Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer.
Authors: Cao BY; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China., Cao Q; Department of Pathology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Ma XT; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China., Ou K; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China., Yang WW; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China., Zhang LT; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China., Lu JY; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China., Jiang ZC; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China., Zhang W; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China., Zhang J; Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing, China., Wang Q; Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing, China., Gao LZ; Department of Medical Oncology, Beijing Chaoyang Huanxing Cancer Hospital, Beijing, China., Yang L; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China. linyangcicams@126.com.
Source: BMC cancer [BMC Cancer] 2025 Mar 12; Vol. 25 (1), pp. 449. Date of Electronic Publication: 2025 Mar 12.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40075310
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Cao+BY%22">Cao BY</searchLink>; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China.<br /><searchLink fieldCode="AU" term="%22Cao+Q%22">Cao Q</searchLink>; Department of Pathology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Ma+XT%22">Ma XT</searchLink>; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China.<br /><searchLink fieldCode="AU" term="%22Ou+K%22">Ou K</searchLink>; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China.<br /><searchLink fieldCode="AU" term="%22Yang+WW%22">Yang WW</searchLink>; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China.<br /><searchLink fieldCode="AU" term="%22Zhang+LT%22">Zhang LT</searchLink>; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China.<br /><searchLink fieldCode="AU" term="%22Lu+JY%22">Lu JY</searchLink>; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China.<br /><searchLink fieldCode="AU" term="%22Jiang+ZC%22">Jiang ZC</searchLink>; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China.<br /><searchLink fieldCode="AU" term="%22Zhang+W%22">Zhang W</searchLink>; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China.<br /><searchLink fieldCode="AU" term="%22Zhang+J%22">Zhang J</searchLink>; Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Wang+Q%22">Wang Q</searchLink>; Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Gao+LZ%22">Gao LZ</searchLink>; Department of Medical Oncology, Beijing Chaoyang Huanxing Cancer Hospital, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Yang+L%22">Yang L</searchLink>; Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China. linyangcicams@126.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100967800%22">BMC cancer</searchLink> [BMC Cancer] 2025 Mar 12; Vol. 25 (1), pp. 449. <i>Date of Electronic Publication: </i>2025 Mar 12.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100967800 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1471-2407 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214712407%22">14712407 </searchLink><i>NLM ISO Abbreviation: </i>BMC Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40075310
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s12885-025-13799-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 449
    Titles:
      – TitleFull: Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cao BY
      – PersonEntity:
          Name:
            NameFull: Cao Q
      – PersonEntity:
          Name:
            NameFull: Ma XT
      – PersonEntity:
          Name:
            NameFull: Ou K
      – PersonEntity:
          Name:
            NameFull: Yang WW
      – PersonEntity:
          Name:
            NameFull: Zhang LT
      – PersonEntity:
          Name:
            NameFull: Lu JY
      – PersonEntity:
          Name:
            NameFull: Jiang ZC
      – PersonEntity:
          Name:
            NameFull: Zhang W
      – PersonEntity:
          Name:
            NameFull: Zhang J
      – PersonEntity:
          Name:
            NameFull: Wang Q
      – PersonEntity:
          Name:
            NameFull: Gao LZ
      – PersonEntity:
          Name:
            NameFull: Yang L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 03
              Text: 2025 Mar 12
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1471-2407
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: BMC cancer
              Type: main
ResultId 1